These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 30108590

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
    Merhi M, Raza A, Inchakalody VP, Siveen KS, Kumar D, Sahir F, Mestiri S, Hydrose S, Allahverdi N, Jalis M, Relecom A, Al Zaidan L, Hamid MSE, Mostafa M, Gul ARZ, Uddin S, Al Homsi M, Dermime S.
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
    Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC.
    Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
    [Abstract] [Full Text] [Related]

  • 4. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C.
    Ann Oncol; 2017 Jul 01; 28(7):1605-1611. PubMed ID: 28419181
    [Abstract] [Full Text] [Related]

  • 5. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M, Jakobsen KK, Grønhøj C, von Buchwald C.
    Oral Oncol; 2019 Mar 01; 90():67-73. PubMed ID: 30846179
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.
    Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL.
    Cancer Immunol Res; 2017 May 01; 5(5):408-416. PubMed ID: 28408386
    [Abstract] [Full Text] [Related]

  • 9. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V, Teusch J, Aljasem A, Schmucker P, Klenk N, Straub A, Bittrich M, Seher A, Linz C, Müller-Richter UDA, Hartmann S.
    Int J Mol Sci; 2020 Nov 20; 21(22):. PubMed ID: 33233528
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
    Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE, McClanahan T.
    Clin Cancer Res; 2017 Jun 15; 23(12):3158-3167. PubMed ID: 28619999
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.
    J Clin Oncol; 2018 Apr 01; 36(10):942-950. PubMed ID: 29394125
    [Abstract] [Full Text] [Related]

  • 18. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
    Kumai T, Komatsuda H, Minami Y, Harabuchi Y.
    ORL J Otorhinolaryngol Relat Spec; 2020 Apr 01; 82(6):343-350. PubMed ID: 32882699
    [Abstract] [Full Text] [Related]

  • 19. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
    Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Muenscher A, Clauditz TS.
    Int J Cancer; 2014 Sep 01; 135(5):1142-52. PubMed ID: 24482145
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.